Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Retinoid signals and Th17-mediated pathology.

Klemann C, Raveney BJ, Oki S, Yamamura T.

Nihon Rinsho Meneki Gakkai Kaishi. 2009 Feb;32(1):20-8. Review.

2.

Synthetic retinoid AM80 inhibits Th17 cells and ameliorates experimental autoimmune encephalomyelitis.

Klemann C, Raveney BJ, Klemann AK, Ozawa T, von Hörsten S, Shudo K, Oki S, Yamamura T.

Am J Pathol. 2009 Jun;174(6):2234-45. doi: 10.2353/ajpath.2009.081084. Epub 2009 Apr 23.

3.

Green tea EGCG, T cells, and T cell-mediated autoimmune diseases.

Wu D, Wang J, Pae M, Meydani SN.

Mol Aspects Med. 2012 Feb;33(1):107-18. doi: 10.1016/j.mam.2011.10.001. Epub 2011 Oct 14. Review.

PMID:
22020144
4.

Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo.

Ohyanagi N, Ishido M, Suzuki F, Kaneko K, Kubota T, Miyasaka N, Nanki T.

Arthritis Rheum. 2009 Oct;60(10):3118-27. doi: 10.1002/art.24930.

5.

Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses.

Walsh KP, Brady MT, Finlay CM, Boon L, Mills KH.

J Immunol. 2009 Aug 1;183(3):1577-86. doi: 10.4049/jimmunol.0803803. Epub 2009 Jul 8.

6.

IFN-beta inhibits human Th17 cell differentiation.

Ramgolam VS, Sha Y, Jin J, Zhang X, Markovic-Plese S.

J Immunol. 2009 Oct 15;183(8):5418-27. doi: 10.4049/jimmunol.0803227. Epub 2009 Sep 25.

7.

The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T cells.

Crome SQ, Wang AY, Kang CY, Levings MK.

Eur J Immunol. 2009 Jun;39(6):1480-93. doi: 10.1002/eji.200838908.

9.

Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.

Kanai T, Nemoto Y, Kamada N, Totsuka T, Hisamatsu T, Watanabe M, Hibi T.

Curr Opin Gastroenterol. 2009 Jul;25(4):306-13. doi: 10.1097/MOG.0b013e32832bc627. Review.

PMID:
19448533
10.

[Retinoid therapy for autoimmune diseases].

Fukasawa H, Kagechika H, Shudo K.

Nihon Rinsho Meneki Gakkai Kaishi. 2006 Jun;29(3):114-26. Review. Japanese.

11.

CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.

Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C, Tubridy N, Mills KH.

J Immunol. 2009 Dec 1;183(11):7602-10. doi: 10.4049/jimmunol.0901881. Epub 2009 Nov 16.

12.

Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease.

Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, Mills KH.

J Immunol. 2009 Aug 1;183(3):1715-23. doi: 10.4049/jimmunol.0803851. Epub 2009 Jul 1.

13.

Protein kinase B/Akt signals impair Th17 differentiation and support natural regulatory T cell function and induced regulatory T cell formation.

Pierau M, Engelmann S, Reinhold D, Lapp T, Schraven B, Bommhardt UH.

J Immunol. 2009 Nov 15;183(10):6124-34. doi: 10.4049/jimmunol.0900246. Epub 2009 Oct 19.

14.

T-bet inhibits the in vivo differentiation of parasite-specific CD4+ Th17 cells in a T cell-intrinsic manner.

Guo S, Cobb D, Smeltz RB.

J Immunol. 2009 May 15;182(10):6179-86. doi: 10.4049/jimmunol.0803821.

15.

RORC2: the master of human Th17 cell programming.

Unutmaz D.

Eur J Immunol. 2009 Jun;39(6):1452-5. doi: 10.1002/eji.200939540.

16.

Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.

Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH.

Immunity. 2009 Aug 21;31(2):331-41. doi: 10.1016/j.immuni.2009.08.001. Epub 2009 Aug 13.

17.

T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.

Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F.

Ann Neurol. 2009 May;65(5):499-509. doi: 10.1002/ana.21652.

PMID:
19475668
18.

Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells.

Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, Sallusto F.

Eur J Immunol. 2009 May;39(5):1301-12. doi: 10.1002/eji.200838969.

19.

Th17 cells in inflammatory conditions.

Cooke A.

Rev Diabet Stud. 2006 Summer;3(2):72-5. Epub 2006 Aug 10.

20.

A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.

Huber M, Heink S, Grothe H, Guralnik A, Reinhard K, Elflein K, Hünig T, Mittrücker HW, Brüstle A, Kamradt T, Lohoff M.

Eur J Immunol. 2009 Jul;39(7):1716-25. doi: 10.1002/eji.200939412.

Supplemental Content

Support Center